Australia's Imugene jumps on cancer trial FDA progress

Imugene

28/11/2023 03:48

Nov 28 (Reuters) -    ** Shares of immunotherapy
developing firm Imugene  IMU.AX  soars as much as 31.9% to
A$0.120, their best day since Nov. 10 if current gains hold 
    ** Stock hits highest level since Nov. 14 
    ** Co says US Food and Drug Administration (FDA) has granted
fast-track designation to its MAST (Metastatic Advanced
Solid Tumours) clinical program for bile duct cancer
    ** More than 75 mln shares change hands, compared with the
30-day average volume of ~71.7 mln
    ** Stock has fallen 37.2% this year, as of last close

 (Reporting by Sneha Kumar in Bengaluru)
 ((Sneha.Kumar@thomsonreuters.com;))